July MIMS update

We look at some of the recent changes to the medicines landscape, with new products, new indications, safety related changes and more New Products Finerenone (Kerendia) is a nonsteroidal antagonist of the mineralocorticoid receptor (MR) that potently attenuates inflammation and fibrosis mediated by MR overactivation. The MR is expressed in the kidneys, heart and blood

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Top 10: Dispensing dominates agenda
Next Protocols, resident empowerment highlighted following death